Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 10/20 | 0.62 |
| ▸ | FLT1 | P17948 | 9/20 | 0.62 |
| ▸ | FLT4 | P35916 | 9/20 | 0.62 |
| ▸ | VCP | P55072 | 4/20 | 0.61 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.48 |
| ▸ | PRKDC | P78527 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23539541 | 0.89 | VCP (0.55) | KDRFLT1FLT4VCPIMPDH2 | |
| SCHEMBL5477362 | 0.84 | MAPT (0.55) | KDRFLT1FLT4VCPPRKDC | |
| SCHEMBL5477528 | 0.84 | VCP (0.80) | KDRFLT1FLT4VCPIMPDH2 | |
| SCHEMBL23539644 | 0.80 | PRKDC (0.51) | KDRPRKDCATM | |
| SCHEMBL5475234 | 0.80 | MAOB (0.54) | KDRPRKDCATM | |
| SCHEMBL5184578 | 0.79 | KDR (0.72) | KDRFLT1FLT4VCPIMPDH2 | |
| Gw549390X SCHEMBL3295009 | 0.78 | KDR (1.00) | KDRFLT1FLT4VCPIMPDH2 | |
| SCHEMBL31061190 | 0.77 | KDR (1.00) | KDRFLT1FLT4VCPIMPDH2 | |
| SCHEMBL14492375 | 0.77 | KDR (0.72) | KDRFLT1FLT4VCPIMPDH2 | |
| SCHEMBL26307286 | 0.77 | KDR (0.84) | KDRFLT1FLT4VCPIMPDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030876-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | Ikena Oncology, Inc. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20230295147-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | ARYL THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20210230153-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | ARYL THERAPEUTICS, INC. | 2021-07-29 | — | — | US | disclosed |
| WO-2021127301-A1 | 4-PHENYL-N-(PHENYL)THIAZOL-2-AMINE DERIVATIVES AND RELATED COMPOUNDS AS ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS FOR THE TREATMENT OF E.G. ANGIOGENESIS IMPLICATED OR INFLAMMATORY DISORDERS | Ikena Oncology, Inc. (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030876-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | AHR, ARNT, HCAR1 | KDR 867/4885FLT1 902/4885FLT4 864/4885 |
| US-20230295147-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | AHR, ARNT, HCAR1 | KDR 867/4885FLT1 902/4885FLT4 864/4885 |
| US-20210230153-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | AHR, ARNT, HCAR1 | KDR 867/4885FLT1 902/4885FLT4 864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.